Patent SG-11201810687S-A (SG)
Title: Serum albumin-binding fibronectin type iii domains
Inventor: DIEM MICHAEL
IPC: A61K38/38
Filed: 2017-06-01
Abstract: 2 3 4 5 6 7 8 9 10 11 12 .* Serum Albumin .* * Centyrins '* Cyno Serum Human Serum W O 20 17 / 210 425 Al • • I • • I (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 December 2017 (07.12.2017) W I POI PCT ill~~~~~~~~ 011101tIIl tun Hol milomonnom oimIE (10) International Publication Number WO 2017/210425 Al (51) International Patent Classification: A61K 38/38 (2006.01) C07K 14/78 (2006.01) A61K 38/39 (2006.01) (21) International Application Number: PCT/US2017/035442 (22) International Filing Date: 01 June 2017 (01.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/345,190 03 June 2016 (03.06.2016) US (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; 800/850 Ridgeview Drive, Horsham, PA 19044 (US). (72) Inventors: DIEM, Michael; 1400 McKean Road, Spring- house, PA 19477 (US). JACOBS, Steven; 1400 McK- ean Road, Springhouse, PA 19477 (US). O'NEIL, Karyn; 1400 McKean Road, Springhouse, PA 19477 (US). RUTKOSKI, Thomas; 1400 McKean Road, Springhouse, PA 19477 (US). (74) Agent: SHIRTZ, Joseph F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS Figure 1 (57) : Fibronectin type III domains (FN3) that specifi- cally bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications. [Continued on next page] WO 2017/210425 Al MIDEDIMOMMIDIRMEM001101011fillIONVOIMIE Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))